Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Avina Singh (NPI 1821201666)

Field	Value
Entity Type	Individual
Organization	Avina Singh
Address	675 E Nicollet Blvd Ste 100
City	Burnsville
State	MN
ZIP	55337
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 8, 2007

Payer Source	Total Paid
Medicare	$971.9K
Medicaid	$0

Key Findings

Specialty and service mix: As a Hematology & Oncology Physician, this provider’s billing pattern is dominated by high-cost oncology infusions and in-office chemotherapy administration. The top revenue code is J9271 (pembrolizumab) with $567.6K in Medicare revenue, and the provider also bills chemotherapy administration codes (96413, 96401, 96417, 96375) and oncology-specific injections (Q5119, J2506), indicating a clinic-focused infusion practice that delivers systemic cancer therapies rather than primarily outpatient primary care services.

Revenue concentration: Medicare revenue is heavily concentrated in a small set of drugs and infusion services — the precomputed top 3 Medicare codes account for 71.5% of this provider's total Medicare revenue. J9271 alone represents $567.6K (61.3% of Medicare revenue), while 99214 and Q5119 contribute $48.3K (5.2%) and $46.1K (5.0%) respectively, showing a single-drug revenue dependency profile typical of oncology infusion sites.

Payer mix / single‑payer dependence: This provider reports $971.9K in lifetime Medicare revenue and has no Medicaid billing on file, so the practice is effectively single‑payer with Medicare as the sole public payer in the dataset. That lack of Medicaid activity limits comparisons across payers and suggests contracting, referral patterns, or patient mix that centers on Medicare beneficiaries.

Competitive standing on top drug use: For the leading oncology drug J9271 the provider ranks #831 of 1841 nationally (54th percentile) and is described in the source as having typical, unremarkable volume for this code; this places the provider near the median for pembrolizumab use rather than among national leaders. Similarly, Q5119 (rituximab biosimilar) sits at #129 of 335 (62th percentile) and is labeled typical, indicating modest national participation in those biosimilar and immunotherapy supplies.

Areas of above‑typical procedural activity: Several chemotherapy administration and infusion add‑on codes show comparatively high percentiles, e.g., 96413 ranks #1256 of 7514 (83th percentile) and 96375 ranks #413 of 5191 (92th percentile) and are noted in the source as typical or unremarkable yet place the provider above many peers for infusion throughput. These higher percentiles suggest the clinic handles a substantial volume of infusion encounters relative to most providers, consistent with an infusion‑center workflow.

Codes with lower relative presence: Some supportive care or specialty drug codes appear relatively low in national standing — for example, J1568 ranks #359 of 381 (6th percentile) and is labeled typical, indicating limited activity with that specific intravenous immune globulin product compared with national peers. Those lower ranks highlight that, while infusion volume is meaningful overall, the provider’s drug mix is concentrated in a few agents rather than broadly distributed across many specialty injectables.

Operational signal from EOM participation and office E/Ms: The provider bills M0010 (EOM monthly enhanced oncology services) with $9.5K in revenue and also records office E/Ms such as 99214 (543 claims, $48.3K) and 99215 (87 claims, $11.7K), indicating a mix of procedural infusion revenue and ongoing outpatient management. This combination supports a practice model that couples recurring infusion visits with longitudinal oncology follow-up rather than episodic consults only.

Tenure and market footprint: The provider’s NPI was enumerated on 2007-05-08 (~19 years ago), indicating long-standing registration and an established presence in the market. Despite nearly two decades of enumeration, national ranks across key codes generally place the provider in the middle of the peer distribution for high-cost immunotherapy use rather than as a dominant national outlier.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

63 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,200	$40	$567.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	540	$90	$48.3K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,100	$20	$46.1K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	1,150	$30	$39.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$100	$38.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	15,170	$1	$30.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	420	$70	$29.8K
J0185	Injection, aprepitant, 1 mg	15,470	$1	$15.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	100	$130	$13.4K
J9394	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg	1,000	$10	$13K

Showing 1–10 of 63

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Avina Singh — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

63 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	7	70	7,200	$40	$323.3K
J1568	5	10	3,560	$30	$141.7K
J2506	6	20	290	$80	$34.3K
Q5119	1	30	1,380	$20	$29.5K
J0881	3	20	10,680	$1	$25.4K
J9217	29	80	80	$130	$17.1K
J0185	4	30	7,800	$1	$11.9K
96413	10	230	70	$100	$11.5K
J9394	1	10	790	$10	$9.5K
99233	1,846	2,570	60	$90	$8.4K

Showing 1–10 of 63

Related Providers

Other providers that share a Tax Identification Number (TIN) with Avina Singh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Holland Center	MN	Developmentally Disabled Services Day Training Agency	$0	$16.3M
Minnesota Oncology Hematology, PA	MN	Hematology & Oncology Physician	$0	$8.1M
Robert Delaune	MN	Hematology & Oncology Physician	$1.9M	$0
Vladimir Hugec	MN	Hematology & Oncology Physician	$1.8M	$0
Yang Liu	MN	Hematology & Oncology Physician	$1.4M	$0
David King	MN	Medical Oncology Physician	$1.3M	$0
Ben Zhang	MN	Hematology & Oncology Physician	$914.4K	$0
Uzma Ali	MN	Hematology & Oncology Physician	$868.9K	$0
Samith Thomas Kochuparambil	MN	Hematology & Oncology Physician	$827.8K	$0
Ryan Funk	MN	Radiation Oncology Physician	$716.7K	$0

Nearby Providers

Other providers in the same ZIP code as Avina Singh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The Lodges Company	MN	Assisted Living Facility	$0	$39.1M
Fairview Health Services	MN	General Acute Care Hospital	$0	$30M
Ind School District 191	MN	Local Education Agency (LEA)	$0	$13.1M
Mental Health Resources, Inc.	MN	Case Management Agency	$0	$12.8M
Community Drug & Alcohol Services Inc	MN	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$12M
Mercy Link, LLC	MN	Home Health Agency	$0	$9.9M
Valley Pain Relief And Wellness Center, PLLC	MN	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$0	$9.3M
Professional Portable Radiologic Services, Inc.	MN	Portable X-ray and/or Other Portable Diagnostic Imaging Supplier	$1.1M	$6.2M
Augustana Emerald Care LLC	MN	Assisted Living Facility	$0	$5.8M
Fairview Clinics	MN	Primary Care Clinic/Center	$0	$4.7M

Avina Singh — Billing Profile & Reimbursement Data

Sign up for Avina Singh — Billing Profile & Reimbursement Data policy alerts

Avina Singh — Billing Profile & Reimbursement Data

Sign up for Avina Singh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References